Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 16/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22828106 | 0.87 | PTGS2 (0.75) | PTGS2KDM4ELMNAALDH1A1MAPT | |
| SCHEMBL24335191 | 0.82 | PTGS2 (0.59) | PTGS2PTGS1 | |
| SCHEMBL24334901 | 0.82 | PTGS2 (0.68) | PTGS2KDM4ELMNAALDH1A1MAPT | |
| SCHEMBL23110876 | 0.82 | PTGS2 (0.68) | PTGS2 | |
| SCHEMBL22828104 | 0.81 | PTGS2 (0.75) | PTGS2LMNAMAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL24334957 | 0.81 | PTGS2 (0.59) | PTGS2PTGS1 | |
| SCHEMBL22827966 | 0.81 | PTGS2 (0.79) | PTGS2 | |
| SCHEMBL23110886 | 0.77 | PTGS2 (0.61) | PTGS2KDM4ELMNAALDH1A1MAPT | |
| SCHEMBL23110602 | 0.76 | PTGS2 (0.63) | PTGS2 | |
| SCHEMBL24334889 | 0.76 | PTGS2 (0.52) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220106275-A1 | RADIOLABELED COMPOUNDS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106275-A1 | RADIOLABELED COMPOUNDS AND USES THEREOF | PAICS, TMEM14C, SLCO1B1 | PTGS2 4365/4885KDM4E 4129/4885LMNA 2728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.